@article{MTMT:34495834, title = {A lipidanyagcsere zavarai endokrin betegségekben = DISTURBANCES OF LIPID METABOLISM IN ENDOCRINE DISORDERS}, url = {https://m2.mtmt.hu/api/publication/34495834}, author = {Harangi, Mariann and Zsíros, Noémi and Tóth, Nóra}, doi = {10.33616/lam.33.0511}, journal-iso = {LEGE ART MED}, journal = {LEGE ARTIS MEDICINAE}, volume = {33}, unique-id = {34495834}, issn = {0866-4811}, abstract = {A dyslipidaemia kulcsszerepet játszik számos cardiovascularis megbetegedés patomechanizmusában. Számos betegnél nem a lipoprotein-anyagcsere primer zavaráról van szó, hanem a dyslipidaemiát valamely „nem lipid” ok magyarázza. Ezen szekunder dyslipidaemiák meglepően gyakoriak, a hátterükben álló eltérések gyakran nem kerülnek felismerésre, hacsak nem keressük őket aktívan. Az endokrin megbetegedések gyakran társulnak dyslipidaemiával, ide sorolható a hypothyreosis, a diabetes mellitus, a Cushing-szindróma, az acromegalia, a hypogonadismus, a növekedésihormon-deficientia, a hyperprolactinaemia és a polycystás ovarium szindróma. A diagnózis felállítása fontos, hiszen a lipideltérések az esetek jelentős részében jól reagálnak az alapbetegség kezelésére. Ezért az endokrin kórképek felismerése a dyslipidaemiás betegek esetén alapvető lépés a rutinkivizsgálás során a hatékony kezelés és a cardiovascularis megbetegedések megelőzése szempontjából.}, year = {2023}, eissn = {2063-4161}, pages = {511-521} } @article{MTMT:33699902, title = {Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies}, url = {https://m2.mtmt.hu/api/publication/33699902}, author = {Sira, Lívia and Zsíros, Noémi and Bidiga, László and Barna, Sándor Kristóf and Kanyári, Zsolt and Nagy, Edit B. and Guillaume, Nicolas and Wild, Damian and Rázsó, Katalin and Andó, Szilvia and Balogh, István and Nagy, Endre and Balogh, Zoltán}, doi = {10.3389/fendo.2023.1095815}, journal-iso = {FRONT ENDOCRINOL}, journal = {FRONTIERS IN ENDOCRINOLOGY}, volume = {14}, unique-id = {33699902}, issn = {1664-2392}, abstract = {Background: Splanchnic vein thrombosis due to co-existing metastatic pancreatic neuroendocrine tumour (pNET) and JAK2V617F mutation is a rare condition. Case report: Here we present a case of a young woman with complete remission of a non-functioning grade 2 pNET with unresectable liver metastases, coexisting with JAK2V617F mutation. Splenectomy and distal pancreatectomy were performed. Neither surgical removal, nor radiofrequency ablation of the liver metastases was possible. Therefore, somatostatin analogue (SSA) and enoxaparine were started. Peptide receptor radionuclide therapy (PRRT) was given in 3 cycles 6-8 weeks apart. Genetic testing revealed no multiple endocrine neoplasia type 1 (MEN-1) gene mutations. After shared decision making with the patient, she gave birth to two healthy children, currently 2 and 4 years old. On pregnancy confirmation, SSA treatment was interrupted and resumed after each delivery. Ten years after the diagnosis of pNET, no tumour is detectable by MRI or somatostatin receptor scintigraphy. PRRT followed by continuous SSA therapy, interrupted only during pregnancies, resulted in complete remission and enabled the patient to complete two successful pregnancies.}, year = {2023}, eissn = {1664-2392} } @article{MTMT:33594906, title = {Alcohol consumption affects the late endocrine consequences of mild traumatic brain injury.}, url = {https://m2.mtmt.hu/api/publication/33594906}, author = {Frendl, István and Erdei, Annamária and Zsíros, Noémi and Katkó, Mónika and Galgóczi, Erika and Nemeti, Zoltan and Bhattoa Harjit, Pál and Kappelmayer, János and Posta, János and Turchányi, Béla and Urbán, Ferenc and Nagy, Endre}, journal-iso = {NEUROENDOCRINOL LETT}, journal = {NEUROENDOCRINOLOGY LETTERS}, volume = {43}, unique-id = {33594906}, issn = {0172-780X}, abstract = {Currently there are no widely applied methods which could identify, at the time of head trauma, those mild traumatic brain injury (mTBI) patients who later develop pituitary dysfunction. The effect of alcohol consumption on post-TBI endocrine dysfunction is unclear.Five hundred and eight TBI patients, 406 of them with mTBI, were studied. Sixty-one patients (46 males, 15 females) were available for follow-up. Admission serum samples were evaluated for S100B protein and markers of alcohol consumption: ethanol level for day-of-injury intake and carbohydrate deficient transferrin (CDT) level for regular alcohol consumption. Regular alcohol consumption was defined as CDT > 1.5%, including both social and heavy drinkers. Admission and one-year follow-up samples were evaluated for pituitary dysfunction.Newly developed pituitary hormone deficiency was found in 16% of mTBI patients. When cohorts developing and not developing late pituitary dysfunction were compared, 30% and 69% of patients were regular alcohol consumers, respectively (p = 0.02). Neither S100B level nor day-of-injury alcohol consumption was predictive of late pituitary dysfunction.The findings of this preliminary study suggest that regular alcohol consumption may protect against the late endocrine consequences of mTBI. Alcohol intake during the weeks preceding mTBI may identify patients at higher risk for late pituitary dysfunction.}, year = {2022}, eissn = {2354-4716}, pages = {239-245}, orcid-numbers = {Bhattoa Harjit, Pál/0000-0002-4909-0065} } @article{MTMT:33049279, title = {A fibrátok helye az antihyperlipidaemiás terápiában}, url = {https://m2.mtmt.hu/api/publication/33049279}, author = {Zsíros, Noémi and Harangi, Mariann}, journal-iso = {HÁZIORVOS TOVÁBBKÉPZŐ SZEMLE}, journal = {HÁZIORVOS TOVÁBBKÉPZŐ SZEMLE}, volume = {27}, unique-id = {33049279}, issn = {1219-8641}, abstract = {Régóta ismert, hogy a posztprandiális hipertrigliceridémia összefüggésben áll a szív- és érrendszeri betegségekkel. Habár a fibrátok a magas triglicerid és az alacsony HDL-koleszterin szint kezelésére alkalmas gyógyszerek, ezen szerek kardiovaszkuláris kockázatra gyakorolt hatását az utóbbi évek-évtizedek kutatásai egyelőre nem tudták megnyugtatóan tisztázni. A jelenleg is érvényben lévő ajánlások szerint a hipertrigliceridémiás (2,3 mmol/L feletti) nagy kockázatú betegek kardiovaszkuláris rizikójának csökkentésére elsőként továbbra is statin kezelés választandó, e mellett az LDL-koleszterin célértéken lévő betegeknek, akiknek triglicerid szintjük 2,3 mmol/L feletti, statin kezelés mellett megfontolandó fibrát tartalmú készítmény bevezetése.Hangsúlyozni kell, hogy az akut pancreatitis megelőzése érdekében 10 mmol/L feletti triglicerid értékek esetén fibrát adása mindenképpen szükséges, de már 5 és 10 mmol/L közötti értékek esetén is megfontolandó ezen szerek indítása. Kiemelendő továbbá, hogy az utóbbi évek vizsgálatai alapján egyre több adat áll rendelkezésre a fenofibrát szerepéről a diabéteszes retinopátia progressziójának csökkentésében.}, keywords = {fenofibrat; hyperlipidaemia; fibrát; kardiovaszkuláris kockázat; triglicerid}, year = {2022}, pages = {357-361} } @article{MTMT:32923065, title = {Clinical Aspects of Genetic and Non-Genetic Cardiovascular Risk Factors in Familial Hypercholesterolemia}, url = {https://m2.mtmt.hu/api/publication/32923065}, author = {Berta, Eszter and Zsíros, Noémi and Bodor, Miklós and Balogh, István and Lőrincz, Hajnalka and Paragh, György and Harangi, Mariann}, doi = {10.3390/genes13071158}, journal-iso = {GENES-BASEL}, journal = {GENES}, volume = {13}, unique-id = {32923065}, issn = {2073-4425}, abstract = {Familial hypercholesterolemia (FH) is the most common monogenic metabolic disorder characterized by considerably elevated low-density lipoprotein cholesterol (LDL-C) levels leading to enhanced atherogenesis, early cardiovascular disease (CVD), and premature death. However, the wide phenotypic heterogeneity in FH makes the cardiovascular risk prediction challenging in clinical practice to determine optimal therapeutic strategy. Beyond the lifetime LDL-C vascular accumulation, other genetic and non-genetic risk factors might exacerbate CVD development. Besides the most frequent variants of three genes (LDL-R, APOB, and PCSK9) in some proband variants of other genes implicated in lipid metabolism and atherogenesis are responsible for FH phenotype. Furthermore, non-genetic factors, including traditional cardiovascular risk factors, metabolic and endocrine disorders might also worsen risk profile. Although some were extensively studied previously, others, such as common endocrine disorders including thyroid disorders or polycystic ovary syndrome are not widely evaluated in FH. In this review, we summarize the most important genetic and non-genetic factors that might affect the risk prediction and therapeutic strategy in FH through the eyes of clinicians focusing on disorders that might not be in the center of FH research. The review highlights the complexity of FH care and the need of an interdisciplinary attitude to find the best therapeutic approach in FH patients.}, year = {2022}, eissn = {2073-4425}, orcid-numbers = {Balogh, István/0000-0003-3397-2829} } @article{MTMT:32815076, title = {A MODY jelentősége a diabéteszes betegek ellátásában: irodalmi áttekintés egy eset kapcsán}, url = {https://m2.mtmt.hu/api/publication/32815076}, author = {Zsíros, Noémi and Paragh, György and Balogh, István and Harangi, Mariann}, journal-iso = {METABOLIZMUS}, journal = {METABOLIZMUS}, volume = {20}, unique-id = {32815076}, issn = {1589-7311}, year = {2022}, pages = {51-58} } @article{MTMT:32501196, title = {CARDIOVASCULAR RISK FACTORS IN NEWLY DIAGNOSED, UNTREATED HUNGARIAN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA}, url = {https://m2.mtmt.hu/api/publication/32501196}, author = {Juhasz, L. and Nádró, Bíborka and Zsíros, Noémi and Paragh, György and Harangi, Mariann}, doi = {10.1016/j.atherosclerosis.2021.06.550}, journal-iso = {ATHEROSCLEROSIS}, journal = {ATHEROSCLEROSIS}, volume = {331}, unique-id = {32501196}, issn = {0021-9150}, year = {2021}, eissn = {1879-1484}, pages = {E181-E181} } @article{MTMT:32036420, title = {PCSK9-gátlók: új lehetőségek a lipidcsökkentő kezelésben}, url = {https://m2.mtmt.hu/api/publication/32036420}, author = {Harangi, Mariann and Nádró, Bíborka and Zsíros, Noémi}, journal-iso = {GYÓGYSZERÉSZ TOVÁBBKÉPZÉS}, journal = {GYÓGYSZERÉSZ TOVÁBBKÉPZÉS}, volume = {14}, unique-id = {32036420}, issn = {1788-9049}, abstract = {A magas koleszterinszint a szív- és érrendszeri megbetegedések egyik legfontosabb kockázati tényezője, melynek csökkentése kiemelt feladat a mindennapi orvosi gyakorlatban. Az életmód kezelés mellett gyakran szükséges a lipidcsökkentő gyógyszerek alkalmazása, melyek közül a statinokat és az ezetimibet széles körben ismerik és használják. Bár a kombinált gyógyszeres kezelés hatékony, az irányelvekben megfogalmazott szigorú célértékek eléréséhez bizonyos esetekben nem elegendő. 2015. óta egy teljesen új hatásmechanizmusú, és minden eddiginél hatékonyabb koleszterinszint csökkentésre alkalmas gyógyszercsoportot vezettek be, a proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) gátló monoklonális antitesteket. Jelenleg az evolocumab és az alirocumab érhető el kereskedelmi forgalomban. Mindkettőt szubkután injekció formájában, kéthetente ajánlott adagolni a korábban alkalmazott gyógyszeres kezelés mellé adva, mely mellett a low-density lipoprotein koleszterinszintje további átlagosan kb. 60%-kal csökken. A kezelés okozta mellékhatások ritkák és enyhék, ezért a kezelés igen népszerű mind az orvosok, mind a betegek körében. A PCSK9 gátló kezelés jelenleg egyetlen, de meghatározó hátránya a magas költség, mely miatt a rászoruló betegek egyedi méltányossági ártámogatással részesülhetnek ebben az új, rendkívül hatékony terápiás lehetőségben.}, keywords = {hyperlipidaemia; kardiovaszkuláris kockázat; PCSK9 gátló; LDL koleszterin}, year = {2020}, pages = {154-157} } @article{MTMT:30646410, title = {Successful plasmapheresis treatment of severe hypertriglyceridemia during late pregnancy}, url = {https://m2.mtmt.hu/api/publication/30646410}, author = {Zsíros, Noémi and Kovács, Beáta and Paragh, György and Balla, József and Harangi, Mariann}, doi = {10.20517/2574-1209.2018.78}, journal-iso = {VESSEL PLUS}, journal = {VESSEL PLUS}, volume = {3}, unique-id = {30646410}, year = {2019}, eissn = {2574-1209} } @article{MTMT:3362281, title = {Plasminogen Activator Inhibitor Type 1: A Possible Novel Biomarker of Late Pituitary Dysfunction after Mild Traumatic Brain Injury}, url = {https://m2.mtmt.hu/api/publication/3362281}, author = {Frendl, István and Katkó, Mónika and Galgóczi, Erika and Boda, Judit and Zsíros, Noémi and Németi, Zoltán and Bereczky, Zsuzsanna and Hudák, Renáta and Kappelmayer, János and Erdei, Annamária and Turchányi, Béla and Nagy, Endre}, doi = {10.1089/neu.2017.5198}, journal-iso = {J NEUROTRAUM}, journal = {JOURNAL OF NEUROTRAUMA}, volume = {34}, unique-id = {3362281}, issn = {0897-7151}, abstract = {More than 80% of head trauma patients suffer from mild traumatic brain injury (mTBI). However, even mTBI carries the risk of late pituitary dysfunction. A predictive biomarker at the time of injury which could identify patients who subsequently may develop permanent pituitary dysfunction would help to direct patients towards endocrine care. We enrolled 508 traumatic brain injury patients (406 with mTBI) into our study. Blood samples were collected for identification of predictive biomarkers of late pituitary dysfunction at the time of admission. Follow-up blood samples were collected between 6 to 12 months after the head trauma and were evaluated for pituitary function. Of the 406 mTBI patients, 76 were available for follow-up. Pre-existing mild pituitary dysfunction was found for 15 patients based on hormone levels at the time of injury. Of the remaining 61 patients, 10 have shown deficiency in at least one pituitary hormone: 4 had growth hormone deficiency, 3 gonadotropin, 2 thyrotropin, and 1 patient combined gonadotropin and thyrotropin deficiency. Hence, newly developed pituitary hormone deficiency was found in 16% of mTBI patients. Neither the cause of mTBI nor its complications were predictive of late pituitary dysfunction. Of the haemostasis parameters studied, lower PAI-1 level at the time of injury was found to be predictive for the development of late pituitary dysfunction; sensitivity, specificity, positive and negative predictive values were 80%, 67%, 32% and 94%, respectively. Even mild TBI carries a substantial risk of endocrine consequences. Serum PAI-1 level at the time of head trauma may serve as predictive biomarker of late pituitary dysfunction in mTBI patients.}, year = {2017}, eissn = {1557-9042}, pages = {3238-3244}, orcid-numbers = {Bereczky, Zsuzsanna/0000-0002-1483-3703} }